Researchers analyzed 11 different studies to understand weight outcomes after stopping anti-obesity medications called glucagon-like peptide-1 receptor agonists, or GLP-1s, which mimic the GLP-1 ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

The order in which you eat your food may affect blood sugar levels, with experts recommending vegetables first, then protein ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

Insulin and glucagon work in what’s called a negative feedback loop. During this process, one event triggers another, which triggers another, and so on, to keep your blood sugar levels balanced ...

Glucagon can also play a role in how amino acids (compounds that help make up muscles and tissue in your body) make glucose. And it can break down triglycerides, or fat your body stores, into fuel.